Inhaled simvastatin nanoparticles for inflammatory lung disease

Alaa S. Tulbah, Elvira Pisano, Santo Scalia, Paul M. Young, Daniela Traini, Hui Xin Ong*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


Aim: Current inhaled treatments are not adequate to treat all lung diseases. In this study, a promising nanotechnology has been developed to deliver a potential anti-inflammatory and muco-inhibitory compound, simvastatin, for treatment of inflammatory lung diseases via inhalation. Materials & methods: Simvastatin nanoparticles (SV-NPs) encapsulated with poly(lactic-co-glycolic) acid were fabricated using the solvent and anti-solvent precipitation method. Results: SV-NPs were found to be stable up to 9 months at 4°C in a freeze-dried form prior to reconstitution. The amount of mucus produced was significantly reduced after SV-NPs treatment on inflammation epithelial cell models and were effective in suppressing the proinflammatory marker expression. Conclusion: This study suggests that SV-NPs nebulization could potentially be used for the treatment of chronic pulmonary diseases.

Original languageEnglish
Pages (from-to)2471-2485
Number of pages15
Issue number20
Publication statusPublished - Oct 2017
Externally publishedYes


  • epithelia transport
  • inflammation
  • inhalation
  • mucus
  • nanoparticles
  • simvastatin
  • stability


Dive into the research topics of 'Inhaled simvastatin nanoparticles for inflammatory lung disease'. Together they form a unique fingerprint.

Cite this